Thermo Fisher (TMO) AI Stock Analysis

• Market Cap: $176.72B
• Dividend Yield: 0.36%
• Average Volume (3M): 1.79M
• Price to Earnings (P/E): 27.2
• Beta (1Y): 0.74
• Revenue Growth: 2.05%
• EPS Growth: 7.03%
• Country: US
• Employees: 125,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 5.36
• Shares Outstanding: 377,612,120
• 10 Day Avg. Volume: 2,229,169
• 30 Day Avg. Volume: 1,794,963
• PEG Ratio: 4.64
• Price to Book (P/B): 4.01
• Price to Sales (P/S): 4.63
• P/FCF Ratio: 27.35
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 4.24
• Enterprise Value/Gross Profit: 10.71
• Enterprise Value/Ebitda: 16.08
• 1Y Price Target: $546.61
• Price Target Upside: 19.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 72 Outperform
• Price Target: $521.00 ▲(13.45% Upside)

Thermo Fisher's overall stock score is driven by its strong financial performance and positive earnings call, which highlight robust operational health and increased guidance. However, technical indicators suggest potential bearish momentum, and the valuation appears high relative to peers, which tempers the overall score.

Positive Factors

Strong Market Presence

Thermo Fisher's extensive product range and established market position across multiple sectors ensure stable revenue streams and resilience against market fluctuations.

Innovation in Analytical Instruments

Continued innovation in high-end analytical instruments strengthens Thermo Fisher's competitive edge and supports long-term growth in the research and diagnostics markets.

Strategic Partnerships

Expanding strategic partnerships enhances product distribution and market reach, bolstering Thermo Fisher's sales channels and long-term revenue potential.

Negative Factors

Academic and Government Revenue Decline

Declining revenue from academic and government sectors may impact Thermo Fisher's growth, as these segments are crucial for scientific research and development.

China Market Headwinds

Market challenges in China, a significant growth region, could hinder Thermo Fisher's revenue expansion and affect its global market strategy.

Impact of Tariffs and Policy Environment

Tariff impacts and policy changes can increase operational costs and reduce profitability, posing long-term risks to Thermo Fisher's financial performance.

Thermo Fisher Business Overview & Revenue Model

Company Description

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Thermo Fisher generates revenue through multiple key streams including the sale of scientific instruments, consumables, and reagents. Its primary revenue sources are divided into four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment focuses on products for drug discovery, development, and production, while the Analytical Instruments segment includes high-end analytical instruments used for quality control and research. Specialty Diagnostics comprises in vitro diagnostics and biological safety testing products. Additionally, Laboratory Products and Services includes a range of lab equipment and services. The company also benefits from significant partnerships with academic institutions, research organizations, and pharmaceutical companies, which facilitate the development and commercialization of innovative solutions. Thermo Fisher's strong market presence and diverse product portfolio contribute to its robust earnings and financial stability.

Thermo Fisher Financial Statement Overview

Summary

Thermo Fisher demonstrates robust financial health characterized by stable profitability, a balanced capital structure, and efficient cash flow management. Strong margins, effective debt management, and solid ROE are notable, though revenue growth is moderate.

Income Statement

Thermo Fisher shows strong profitability with a stable Gross Profit Margin of approximately 41.74% for TTM. The Net Profit Margin is 15.24%, indicating efficient cost control and profitability. Revenue growth has been modest with a TTM increase of 0.78% compared to the previous year. EBIT and EBITDA margins are healthy at 17.13% and 19.58%, respectively, reflecting robust operational performance.

Balance Sheet

The company's financial position is solid with a manageable Debt-to-Equity Ratio of 0.70. Return on Equity (ROE) stands at 13.05%, showcasing effective use of equity. The Equity Ratio of 49.85% highlights a balanced capital structure. Overall, the balance sheet indicates stability with a slight increase in liabilities over time.

Cash Flow

Operating Cash Flow to Net Income Ratio is 1.15, indicating strong cash generation. The Free Cash Flow has decreased by 15.09% from the previous year, reflecting higher capital expenditures. The Free Cash Flow to Net Income Ratio is 0.94, suggesting efficient cash flow management despite investment activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.21B	42.88B	42.86B	44.91B	39.21B	32.22B
Gross Profit	17.10B	17.73B	17.19B	19.01B	19.63B	16.03B
EBITDA	11.40B	11.80B	11.20B	11.94B	11.97B	10.11B
Net Income	6.58B	6.33B	6.00B	6.95B	7.72B	6.38B
Balance Sheet
Total Assets	101.23B	97.32B	98.73B	97.15B	95.12B	69.05B
Cash, Cash Equivalents and Short-Term Investments	6.39B	5.57B	8.08B	8.52B	4.48B	10.32B
Total Debt	35.23B	32.77B	36.42B	36.07B	36.34B	22.55B
Total Liabilities	50.63B	47.65B	51.88B	53.01B	54.15B	34.53B
Stockholders Equity	50.51B	49.58B	46.73B	43.98B	40.79B	34.51B
Cash Flow
Free Cash Flow	6.17B	7.27B	6.93B	6.91B	7.02B	6.82B
Operating Cash Flow	7.58B	8.67B	8.41B	9.15B	9.54B	8.29B
Investing Cash Flow	-4.37B	-5.84B	-5.14B	-2.16B	-21.93B	-1.51B
Financing Cash Flow	-5.95B	-6.79B	-3.62B	-2.81B	6.58B	959.00M

Thermo Fisher Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 459.22
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TMO, the sentiment is Negative. The current price of 459.22 is below the 20-day moving average (MA) of 481.91, below the 50-day MA of 472.98, and below the 200-day MA of 478.15, indicating a bearish trend. The MACD of -0.80 indicates Positive momentum. The RSI at 43.78 is Neutral, neither overbought nor oversold. The STOCH value of 17.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TMO.

Thermo Fisher Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	77 Outperform	35.26B	29.17	19.15%	0.80%	4.48%	-11.52%
IDXX	77 Outperform	50.18B	51.45	67.56%	―	6.68%	18.84%
IQV	77 Outperform	30.81B	25.59	21.41%	―	3.53%	-10.72%
TMO	72 Outperform	$176.72B	27.19	13.44%	0.36%	2.05%	7.03%
DHR	69 Neutral	133.12B	39.49	6.52%	0.68%	-3.24%	-16.60%
WAT	69 Neutral	17.42B	25.94	30.62%	―	5.89%	10.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Thermo Fisher Corporate Events

Thermo Fisher Completes $4 Billion Solventum Acquisition

On September 2, 2025, Thermo Fisher Scientific completed its $4.0 billion acquisition of Solventum Corporation’s purification and filtration business, enhancing its bioprocessing and adjacent market offerings. The acquisition is expected to generate $750 million in revenue for 2025 and provide significant growth and synergy opportunities, although it will initially be dilutive to adjusted EPS by $0.06. The transaction strengthens Thermo Fisher’s portfolio with advanced filtration technologies, expanding its reach in industries requiring ultra-pure water, such as battery, semiconductor, and medical device manufacturing.

Thermo Fisher Announces CFO Retirement and Successor

On July 23, 2025, Thermo Fisher Scientific Inc. announced that its Senior Vice President and Chief Financial Officer, Stephen Williamson, will retire effective March 31, 2026. James R. Meyer, currently Vice President of Financial Operations, will succeed Williamson as CFO starting March 1, 2026, bringing extensive experience within the company since joining in 2009.